Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed a Schedule 13G Amendment No. 1 with the SEC on November 13, 2026, disclosing beneficial ownership positions in Faeth Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Montanova Capital and Aaron Cowen: each reported beneficial ownership of 2,310,703 shares, representing 8.9% of Faeth Therapeutics common stock.
  • Averill Master Fund, Ltd.: reported beneficial ownership of 1,969,872 shares, representing 7.6% of the class.
  • Voting and dispositive power: all three reporting persons hold zero sole voting or dispositive power; all reported shares are held with shared voting and shared dispositive power only.
  • Advisory client ownership: according to the filing, all securities reported are "directly owned by advisory clients of Montanova Capital, LLC," with Averill Master Fund, Ltd. identified as the only advisory client holding more than 5% of the common stock.
  • Triggering event: the date of the event requiring the filing was September 30, 2026.
  • Security covered: Common Stock, $0.0001 par value per share, CUSIP 81728A207.

Montanova Capital and Aaron Cowen's Position in Faeth Therapeutics

The Schedule 13G Amendment No. 1, filed November 13, 2026 for Faeth Therapeutics, Inc. (CUSIP 81728A207), names three reporting persons: Montanova Capital, LLC, a Delaware-organized investment adviser; Averill Master Fund, Ltd., a Cayman Islands company; and Aaron Cowen, a United States individual. The filing covers common stock, $0.0001 par value per share, of Faeth Therapeutics, whose principal executive offices are located at 701 Tillery Street #12 #1010, Austin, Texas 78702.

According to the filing, Montanova Capital and Aaron Cowen each beneficially own 2,310,703 shares, equal to 8.9% of the class. Averill Master Fund separately reports 1,969,872 shares, equal to 7.6%. In each case, the filing shows zero sole voting power and zero sole dispositive power, with all reported shares attributed to shared voting power and shared dispositive power. The filing states that "all of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC" and that none of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the common stock.

The filing was signed on November 13, 2026 by Andrew Nathanson, identified as General Counsel and Chief Compliance Officer of Montanova Capital, LLC, and as Authorized Signatory for Averill Master Fund, Ltd. Aaron Cowen signed separately. Each reporting person included a disclaimer stating that the report "shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."

What Was Disclosed

Three reporting persons - Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen - filed an amended Schedule 13G disclosing aggregate beneficial ownership positions in Faeth Therapeutics common stock, with Montanova Capital and Aaron Cowen each at 8.9% and Averill Master Fund at 7.6%, all as of September 30, 2026.